NexgenRx records a 19.31% Q2 2024 revenue increase to $4.08M, driven by transaction, admin revenue growth, and SaaS adoption.

NexgenRx, a Canadian TPA & tech provider, records 19.31% Q2 2024 revenue increase to $4.08M, driven by transaction, admin revenue growth, and SaaS adoption. Positive EBITDA rises by 17% to $376.5K, maintaining a strong cash position of $1.809M. NexgenRx focuses on developing SaaS solutions for clients to manage benefit plans effectively.

August 15, 2024
4 Articles